A Randomized, Placebo-Controlled, Double-Blind, Clinical Trial Evaluating Two Dose Regimens of Rifaximin (550 mg Daily or 550 mg Twice Daily) for Chemoprophylaxis Against Travelers' Diarrhea (TD) Among Active Duty Deployed U.S. and British Military Personnel

Trial Profile

A Randomized, Placebo-Controlled, Double-Blind, Clinical Trial Evaluating Two Dose Regimens of Rifaximin (550 mg Daily or 550 mg Twice Daily) for Chemoprophylaxis Against Travelers' Diarrhea (TD) Among Active Duty Deployed U.S. and British Military Personnel

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2016

At a glance

  • Drugs Rifaximin (Primary)
  • Indications Reactive arthritis; Traveller's diarrhoea
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jun 2016 Planned End Date changed from 1 Sep 2016 to 1 Nov 2017.
    • 06 Jun 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Mar 2017.
    • 06 Jun 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top